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BACKGROUND
In 1994, we attended a superb meeting that brought together many
researchers studying prostate cancer (PCa). The standard of talks
was outstanding. Initially, we felt elated and inspired by the data
and discussions generated. Future possibilities seemed endless. On
reflection however, it became obvious that almost none of the data
presented, which had cost millions of pounds and taken thousands of
man hours to complete, had had any immediate, medium or even
long term impact whatsoever on the clinical management of patients
with PCa. It was not immediately apparent why this should be.
However, most of the researchers were basic science orientated
and the relatively minor input of clinicians may have been an
important factor. Also, many of the speakers had been previously
working on molecular aspects of other tissue and organ systems,
including cancers, but were exploring the possibility of applying
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their technology to prostate disease as increased PCa funding was
starting to trickle through. We were also reminded of the difficulties
that we had personally experienced when trying to engineer
collaborations in the past. It became apparent that very clear
agreements needed to be made before these could take place and
the kind of trust required to develop them took some time to build.
Issues such as order of authorship, principal investigator status,
contributions to concepts, which group did which elements of the
work and the specifics of a time frame were essential to agree
before starting work. How these were resolved in practice could
make a real difference to whether collaborations were short term
or continued over many years and with increasing success.
So it became an aspiration to work toward developing inter-
specialty collaboration and help bridge the gap between clinicians
and scientists. One potentially useful route would be to attempt a
text, which mixed clinical and scientific contributions. Its primary
objective would be to provide a clear explanation of PCa as perceived
by specialists so that non-specialists could understand issues outside
their areas of expertise. We felt this was more of a priority than
being right up to date. Without interdisciplinary cross talk, scien-
tists may take the path of pure molecular and cellular research, in
itself a noble object but perhaps less likely to meaningfully impact
upon clinical practice. At the same time, clinicians need an
understanding of what science can offer and how they too have an
important role to play in the process, maybe by coaxing scientific
colleagues toward answering questions that could have translational
significance. By working together, the sum of both groups should be
greater than that achieved by either alone.
We discuss below a number of the issues we perceive that may
be impeding progress.
TRANSLATIONAL RESEARCH
In the past 100 years or so there has been little in the way of
meaningful advances in the clinical management of PCa apart from
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Huggins discovery of the androgen regulation of the prostate in the
1940’s. Yet during this period, and especially the past 25 years,
there has been an explosion in biomedical knowledge. The last 10
years has brought high throughput technologies including genomics,
proteomics and micro-array technologies and the entire human
genome is now unravelled. But there remains a very wide gap
between laboratory findings and clinical applications at the bedside
and there are few parallels between major scientific advances and
advances in patient management. Waldmann has said “there is a
need to translate these fundamental scientific insights into new
approaches for prevention, diagnosis and treatment of human
disease for the benefit of patients and this can only be addressed by
patient orientated clinical research”.1 Why are there such problems?
IMPEDIMENTS TO PROGRESS OF TRANSLATION
RESEARCH
Translation involves the application of basic science discoveries
into clinically germane findings and simultaneously the generation
of scientific questions based on clinical observations.2, 3 Pober et al.2
believe that translation is not a straightforward process but a new
form of research in its own right and therefore problems arise as a
direct result. Many impediments exist and compromise progress as
a consequence and some are discussed below.
There is a shortage of suitable trained individuals to undertake
translational research. The skills to address this are usually not
available in a single laboratory or clinical setting and Pober et al.
suggest the need for academic medical centres as a model to conduct
translational research. These consist of combined Medical Schools
and Hospitals because such institutions tend to accommodate both
clinical and laboratory based investigators. However, they are
30–40% more expensive than non-academic hospitals.4 This is
hardly surprising when the duration of training these investigators
can exceed well beyond 10 years. Yet such individuals have
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increasing pressure on them to meet service rather than research
needs. Focusing on science may be a major disincentive as it
limits personal income and/or the ability to sustain critical skills,
for example in operative surgery, which compromises credibility
amongst peers. Additional disincentive derives from the academic
culture in which principal investigator status on grants and/or
senior authorship on papers undermine rewards for collaborators
who are essential but do not have either of these leadership roles
and therefore do not receive recognition for their contributions.
Institutions may deny them promotion as a result.6,7 Translational
studies tend not to be adequately represented within the leadership
of academic institutions and are low down in the hierarchy.
Like Pober et al., and the contributors to this book, we have little
difficulty identifying opportunities to combine basic and clinical
research in our own field (see next section). However, translational
research is expensive and more complicated to undertake. Funding
of clinical and scientific components tend to come from separate
sources. Hypothesis driven research generally tends to be favoured
over applied research by funding bodies but is much more difficult
to carry out on human subjects as opposed to laboratory models
in which the primary criterion is scientific rigour. Academic medical
centres appear to have little influence to challenge the prevailing
status quo and in support of translational research. Research
programmes also need support staff and other resources. For
example, writing, administrative, financial and technical skills are
needed to run the grants and physically do the projects. Such
resources usually come through departments, structures that do not
lend themselves to the support of interdepartmental collaborations,
which therefore become far more difficult to sustain. Also within an
academic medical centre, there is often physical separation between
basic scientists and clinicians as they are split into departments
within their own disciplines as opposed to multi-disciplinary
groups, diminishing communication and therefore understanding
and cooperation. Further difficulties arise because clinicians and
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basic scientists have difficulty in recognising the relative merits of
each other’s work. Institution and institutionalised bureaucracy can
also sap energy and unintentionally reduce the ability of committed
individuals to deliver high quality research.
Together with all these factors, complying with the deluge of
new regulations to protect patients and their rights (essential
though they are) add to the researchers’ work load and act as
further disincentives to research involving humans. There may also
be conflict of interests in which the needs of patients are weighed
against financial gain. Ethics committees are essential in regulating
these aspects but have a fine line in which to balance the relative
merits. They champion and safeguard the patient and are a vital
component of the system but the translational researcher can be left
in a rather solitary position as the only advocate for the research.
SOME CHALLENGES OF PCa
We believe there are three major challenges where translational
research could make a major impact in the management of patients
with PCa and those of us who seek to improve their lot. Our
examples include:
(1) Identify and distinguish between sub-groups of patients with
organ confined PCa that is (a) clinically significant, genuinely
localised, likely to do harm within the patients life time and
therefore have the potential to be eradicated with local radical
therapy compared to (b) clinically significant and potentially life
threatening PCa that are apparently organ confined but where
occult metastases have developed and in whom local radical
therapy would not impact eventual outcome compared to (c)
clinically insignificant, not life threatening PCa and where
radical therapy is unnecessary but if offered, outcome is
not impacted and harm could be caused. This challenge
will become increasingly important as screening programmes
identify potentially large numbers of patients who would not
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otherwise have presented clinically and who may never develop
significant disease.
(2) Develop treatments for extra-prostatic disease i.e. that for which
there is currently no curative therapy and
(3) Understand the psychological processes involved in decision
making on an individual basis as both clinicians and patients
explain and rationalise about the management of the disease.
To achieve these will require improved tumour markers (serum/
urine/tissue), improved imaging, better targeting and advances in
technology. Patients and researchers will have to spend more time
together. There will also need to be a change in culture because
as an increasing evidence base accumulates, entrenched opinion
from supporters of views at the extremes of the varied management
options will, through clinical governance and peer pressure, be
required to alter their clinical practice toward the mainstream.
SOME CONTROVERSIES AND PCa
Much of the current state of knowledge regarding PCa is covered
in the book and we do not intend to give a mini-overview here.
However, we felt it would be of interest to look at some of the
aspects of PCa where uncertainty and sincerely held but often
entrenched, dogmatic opinion exists without definitive evidence in
support. We want to provoke controversy and perhaps identify some
areas where the different stake holders and their vested interests
could influence judgement. These include the health care industry
(doctors, hospitals, pharmaceutical and technology companies, etc)
as well as perhaps most importantly patients and their advocate
groups themselves. We are all familiar with those who “know” that
they can cure PCa and that screening will decrease mortality
equally as well as those who “know” that no such benefits are
possible. Hopefully, it will be possible to encourage impartial
objective dissection of the evidence with the ultimate aim being
beneficial to the patients and their families.
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It may be helpful to review other cancers to examine how
changes in perception of disease have impacted mortality and
morbidity. PCa remains a relatively new area of research by
contrast to for example breast cancer, which has been occupying an
increasingly important place in the political agenda for the past 30
years or so. It is astonishing to think that in the late 1960’s, there
was very little research targeted at women’s health.8 The surgeons
of the early part of the last century believed that the reason for
failure of local treatment for breast cancer (i.e. mastectomy) was
that it was insufficiently radical. So first they advocated the removal
of pectoralis major, then pectoralis minor with axillary lymph node
clearance, to be subsequently followed by the internal mammary
lymph node chain, requiring thoracotomy. The unfortunate women
who underwent this mutilating surgery suffered severe sequelae
from treatment but with no identifiable cancer specific survival
advantage. The pendulum has since swung the other way and it is
now recognised that breast cancer should be considered a systemic
disease at diagnosis and managed accordingly. Minimally mutilating
surgery to minimise the risk of local recurrence is the current
treatment of choice along with adjuvant cytotoxic chemotherapy and/
or hormone therapy to try and impact systemic disease. These
recent changes in management have resulted in improvements
from an average baseline 10-year mortality of 40% in 1985 into
an increased absolute survival benefit of 10% by 2000.9 These
data suggest modern treatment ensures that for every 100 women
treated, 10 more are alive today than may have been 15 years
ago.
By contrast, men’s health has only recently begun to climb up
the political agenda and PCa become one of the key targeted
diseases. It is sobering to consider that the first radical prosta-
tectomy was performed in the early 1900’s and it is only now,
almost 100 years later, that any meaningful trials are reporting
its impact in comparison to other radical therapies or watchful
waiting. How could this delay have happened?
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Most recently, Holmberg et al.10 in a randomised trial of 695
men followed for a median of > 6 years compared radical prostatec-
tomy and watchful waiting. They reported a significant decrease in
disease specific mortality but no significant difference between the
two arms in terms of overall survival. The trial began before the
onset of PSA screening and was limited to patients with well or
moderately differentiated disease only. However, it could be inter-
preted from these early data that patients may be damned whether
they have surgery or not! Most trials should report in the next
decade during which period it is to be hoped that management
guidelines become clarified. Aggressive local therapy of PCa is
becoming more frequently practised and it will be interesting to look
back in say 20 years time at the results of current trials (when
hopefully the data are mature and the questions will be answered),
at its impact on disease outcome. With the current ease of access to
massive amounts of information, it has become increasingly difficult
to randomise patients. Imaginative strategies such as the ProtecT
study11 may assist in improving recruitment and enable faster
outcome data as patients themselves elect to undergo one or other
treatment.
There are other possibly important parallels between breast and
PCa, none more so than in the area of screening.
DEVELOPMENTS AND CONTROVERSIES IN SCREENING:
WHO IS CONTROLLING THE AGENDA?
Some Screening Issues
The kind of emotive responses engendered by potentially life-
threatening illnesses and cancer in particular were dramatically
illustrated by a series of commentaries, which appeared recently
in the San Francisco Chronicle.12 Late in 2001, an article was
published about the manager of San Francisco’s baseball team. A
diagnosis of PCa had followed “routine” PSA testing and resulted
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in radical, potentially curative, surgery. His doctors were quoted
as saying “this was the surest way to prevent return of the disease”.
The editor and deputy editor of the Western Journal of Medicine
(Yamey & Wilkes) decided to respond by writing what they con-
sidered to be a “balancing” article in January 2002 for the news-
paper.13 The resulting outpouring of vitriol from advocates of PSA
screening from all walks of life in response suggested at best a
lack of objectivity in interpreting data and at worst a deliberate
intention to prevent debate, silence critics and use emotional
arguments to push forward without scientific enquiry a screening
agenda that even the most fervent advocates of screening will
usually agree may also have the potential to do harm. Yamey &
Wilkes also raised the spectre of the influence of vested interests
that encourage (or discourage) screening and potentially bias con-
sumers and purchasers.
Advocates of PSA screening bombarded their email in-boxes with
accusations, abuse and threats, in which they were compared to
Mengele and accused of having the future deaths of hundreds of
thousands of men on their hands. Some wrote wishing that they
themselves would get PCa. Others argued that only urologists were
qualified to talk about PSA testing. Letters flooded into the office of
the Chancellor of the University of California and the Dean of the
University of California Davis Medical School urging that they be
disciplined or sacked. Dick Warder, founder of Prostate Cancer
Awareness (www.pca.awareness.net) was sufficiently disturbed to
write to the BMJ of his personal experience.14 This was of a (so far)
successful outcome to radical intervention following screening for
his own PCa which was compared to that of an acquaintance with
a raised PSA who died of PCa after declining therapy when
asymptomatic. These anecdotal episodes were used as informed
arguments in favour of screening along with an unreferenced quote
that PCa mortality has declined 18% from 1993 to 1998 and led to
his belief that “screening works” and that he represents “survivors
who object to distortion of evidence”. In fact, SEER data suggest
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that the five year PCa mortality is slightly higher now than in the
1950’s, despite that five year survival has increased from 40% in the
1950’s to about 95% currently. Five-year survival is affected by
diagnostic practice: the incidence of PCa in the USA has increased
about 3-fold over the same period. Data may appear to be improved
by artificial artefacts such as for example deaths postponed (lead-
time bias) rather than avoided, a regular criticism of screening.15, 16
To counter balance Ward’s advocacy, unfortunately also with
anecdote, Lewis was reported as stating that his father nearly died
from the side effects of a prostate biopsy that followed a PSA test
(the biopsy result was negative).17
At least with PCa there is an opportunity to test the hypothesis
that screening may impact on mortality at an earlier stage of devel-
opment and many very large studies are underway. Such controver-
sies as above also attach to the breast cancer screening project.
However this is now so ingrained in western psychology, with
substantial investment of US$3–4 billion annually and 30 million
US women having mammography every year, that randomised trials
appear to be almost impossible to conduct.18 Charatan quotes an
article in the New York Times (NYT) at the end of January 200019
describing a committee of cancer experts, the Physician Data Query
screening and prevention editorial board (PDQ Board), which had
found insufficient evidence to demonstrate that screening mammo-
grams prevented breast cancer death.20 An NYT editorial pointed
out that a great deal of money was at stake on this issue and
predicted considerable difficulty in achieving an independent review
of benefits of screening mammography: “a mammography has been
so strongly endorsed by the cancer establishment and become such
a significant source of revenue… for many hospitals and doctors,
that it may be difficult to excise without overwhelming evidence that
it is dangerous”. A recent Cochrane review concluded that “currently
available evidence does not show a survival benefit of mass
screening for breast cancer (and the evidence is inconclusive for
breast cancer mortality)”.21 Balancing articles appeared later,
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including those from the National Cancer Institute (which uses the
PDQ Board to provide information for its on-line database) and said
that women should continue to attend for mammograms. It is very
disappointing that it was left to the broad sheet press to conclude
the debate (by way of an editorial saying “a serious and open
assessment of the data is crucial”), rather than clinicians and
scientists.
Wells believed that the debate over screening for breast cancer
amongst women in their forties had assumed an importance out of
proportion to its potential impact on public health and illustrated
some of the many obstacles to putting research findings into clinical
practice. She suggested that in the absence of an unequivocal
answer, and when professionals responsible for promoting the best
interests of patients disengage, involvement of patients interest
groups and politicians results in loss of objectivity.22
Entrenched arguments in favour of or against screening some-
how need to be translated, using solid reliable evidence, into
practical advice that is understandable and useable in every day
practice by clinicians and patients. It should not be left to the
lay press to impress this kind of value judgement on patients and
the medical establishment, nor should it be necessary for them to
advocate for the need for measured and objective criteria, especially
when having to explain difficult and controversial diagnostic and
therapeutic options and where the natural history of the disease is
still so inadequately understood. Clinicians and scientists need to
demonstrate objectively where possible. Where evidence is lacking,
they should present current knowledge along with its benefits and
limitations.
de Lemos has suggested23 that the first step to resolving this
controversy should be to ensure that all interested parties agree
and understand the questions that need to be addressed. He implied
that because of the manner in which the debate had evolved
between stakeholders, differences appeared to be irreconcilable
because they each had very different numbers in mind needed to
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test. In his view, this should start with identification of how many
men need to be tested to identify one PCa or prevent one death.
Using contemporary references, he calculated that PSA screening
could prevent one death related to PCa per 100 men tested, accept-
ing that there were potential errors in his calculations.
All the major bodies with an interest in PCa, whether in favour
or against screening, support that men receive information sufficient
to enable them to make a fully informed decision about diagnosis
and future therapy. It has been estimated that this may take at
least up to 20 minutes, an important but very costly exercise.24
In the debate over screening, it remains unknown, which of
these arguments may be right or wrong. Irrespective, attempts at
silencing and even destroying critics of PSA screening in what
appears to be rational debate seem rather sinister as well as
shameful. As a result, we felt even more strongly encouraged to
seek out answers and evidence, outcomes likely to be delivered
faster and with greater accuracy when clinicians and scientists
collaborate together and “bridge that gap”.
DECISION MAKING
Bank’s asserts that men do care about health issues, but feel unable
to talk about their concerns or often fail to seek help until it is too
late.25 This is confounded by the impact of social class, morbidity and
mortality increasing in direct proportion to the level of depravation.
In order to inform patients and enable them to participate in
decision making, it is obviously essential that we know what they
want to know on an individual basis. We also need to try and
understand our own behaviour and how this impacts on the manner
in which we present information and influence the decision making
process. Thus, although most urologists acknowledge the importance
of quality of life in the treatment of PCa, surgical training demands
cure and it can be difficult to reconcile these sometimes conflicting
demands with surgical training.26 Most patients with PCa appear
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to want to share decision making with the doctor27 and to consult
with their partner.28 There are decision making tools available.29 It
seems important to understand these points so that whilst for
examples oncologists recognise the importance of communication
skills and receive training to improve their ability to detect and treat
psychological distress,30 urologists may not be so aware that there is
a problem and training has been lacking. As is increasingly
becoming apparent, gender also influences how patients perceive
and process information and that psychosocial differences affect
coping style, psychological distress and patients partners.31 It is
therefore not appropriate to extrapolate for example the considerable
data currently available on these aspects regarding women and
breast cancer and apply it automatically to men with for example
PCa. It is important that patients be fully involved in the decision
making process. Shared decision making has been recognised as
more effective, relevant and appropriate than the traditional patient
directed model.32, 33 Fallowfield34 argues that a desire for informa-
tion does not equate to a desire to participate in decision making.
We need ways to identify which patients require what information
from us as well as training to deliver these objectives.
INFLUENCE OF HEALTH CARE POLICIES ON
PROVISION OF HEALTH CARE
We have already mentioned the impact of economics and politics
on screening issues. In addition, policies on health care financing
have also been shown to influence clinical management in many
conditions. For example, one study suggests that the absence of
insurance for tubal ligation resulted in caesarean section being
used as an opportunity for clandestine tubal ligation.35 Another
suggests that the business ethos in health care in Chile encouraged
“pragmatism” amongst doctors who do not have a moral objection to
non-medical caesarean section.36 Reports of any factors other than
patient well being that influence clinicians in managing care may
(04)p1ch01.p65 4/26/04, 3:00 PM15
PROSTATE CANCER - Clinical and Scientific Aspects: Bridging the Gap
© Imperial College Press
http://www.worldscibooks.com/medsci/p265.html
16 P.D. Abel & E-N. Lalani
compromise our moral high ground as individuals trusted with the
guardianship of the care for our patients. The US Institute of
Medicine, National Academy of Sciences has stated that where
hospitals and doctors improve quality of care for patients, they often
lose money. For example, appropriate use of peri-operative anti-
biotics reduces complications and improves outcomes but decreases
income for the hospital. New strategies for incentivising health care
systems could have real impact in redefining management.37 As
clinicians and scientists, we need to demonstrate, and be shown to
have demonstrated the highest standards of objectivity without
bias if we are to maintain the high level of respect and faith afforded
to us by our patients.
CONCLUDING COMMENTS
This book has come to fruition over four years and a personal input
of over 2 500 hours. It has proved a huge task, but we have learnt
an enormous amount and believe it was worth it. In this chapter,
we have skimmed through just a few of the areas we believe are
important from a general as well as specific PCa related perspective.
We hope the wealth of information in this book will be easy to
assimilate, stimulate debate and help contribute to bridging the gap
between scientists and clinicians.
We hope the book will be successful and then to apply the
lessons learnt to improve further editions in the future. We
acknowledge and thank all the contributors for their hard work.
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